Sebastian

This marks the first-ever collaboration between Engine Biosciences and Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development. The partnership will advance the development of first-in-class precision therapeutics for multiple cancer types that are highly prevalent in Singapore and globally, including breast, liver, kidney and prostate cancers. Engine Biosciences (Engine), a […]

In September 2024, we showcased our phase 1 dose escalation study for EBC-129 (NCT05701527) at European Society for Medical Oncology (ESMO) Congress.   Further to the ESMO poster presentation, we are happy to announce that we have completed enrolment of the pancreatic ductal adenocarcinoma (PDAC) cohort in the ongoing dose expansion part of EBC-129’s Phase

EDDC is excited to share that we will be collaborating with Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, to bring forward an innovative approach for early drug discovery and development. In this partnership, Partex will initially use its “Asset Exchange” technology platform to identify novel indications for EDDC’s portfolio assets. The parties

EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets cancer cells across a range of solid tumours. The Phase 1 trial for EBC-129 began with a dose escalation study in May 2023. The trial has entered into dose expansion as of 13 May 2024. With the initial safety and

EDDC is proud to share that we are embarking on a partnership with ImmunoScape to develop novel T cell receptor-based therapeutics!  Under the terms of the agreement, ImmunoScape will contribute their repertoire of highly potent tumor-specific TCR candidates to EDDC’s expertise in therapeutic protein design and antibody engineering, to jointly develop innovative off-the-shelf TCR-based bispecific

XtalPi and EDDC embarks on a new collaboration with the signing of this MoU. This agreement builds and expands from an ongoing collaboration that utilizes AI and automation to accelerate the drug discovery program for non-small cell lung cancer (NSCLC). With XtalPi’s automation resources and AI capabilities complimenting EDDC’s industry know-how in drug discovery and